丰倍生物 (603334.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

21.4x

Market Cap

CNY 4.48B

MomentumView details →

1D Return

−4.44%

YTD Return

−25.57%

RSI (14)

41.5

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

21.4x

Market Cap

CNY 4.48B

RSI (14)

41.5

MomentumView details →

1D Return

−4.44%

YTD Return

−25.57%

ProfitabilityView details →

Gross Margin

7.17%

Net Margin

4.01%

EBITDA Margin

5.07%

ROE (TTM)

8.32%

ROA (TTM)

6.68%

Asset Turnover

1.65x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+22.89%

EPS CAGR 3Y

−0.53%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.07x

Current Ratio

4.03x

Quick Ratio

2.94x

Div Yield

1.13%

Div Rate

CNY 0.35

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

3.61B

Net Income (TTM)

144.76M

Op. CF (TTM)

88.64M

Latest newsMore news →

Fengbei Biotech announced its H1 2026 results: revenue of 2.347 billion yuan, up 58.76% year-on-year; net profit attributable to shareholders of 81.4251 million yuan, down 4.28% year-on-year.13d ago

Similar companies

Amicus Therapeutics, Inc.FOLD Dyne Therapeutics, Inc.DYN Ocumension Therapeutics01477.HK Enliven Therapeutics, Inc.ELVN Edgewise Therapeutics, Inc.EWTX Celcuity Inc.CELC Find similar companies →

Latest newsMore news →

Fengbei Biotech announced its H1 2026 results: revenue of 2.347 billion yuan, up 58.76% year-on-year; net profit attributable to shareholders of 81.4251 million yuan, down 4.28% year-on-year.13d ago